Adjunctive quetiapine may help fluvoxamine-resistant obsessive-compulsive disorder among female in-patients: A randomized-controlled study

References

• Sasson Y, Zohar J, Chopra M, et al. Epidemiology of obsessive compulsive disorder: a world view. J Clin Psychiatry. 1997;58(12):7–10.
   Google Scholar
• Katona C, Cooper C, Robertson M. Psychiatry at a glance. 5th ed. Oxford: Blackwell; 2012. p. 30–31.
   Google Scholar
• Piallat B, Polosan M, Fraix V, et al. Subthalamic neuronal firing in obsessive-compulsive disorder and Parkinson disease. Ann Neurol. 2011;69:793–802.
   PubMed Web of Science ®Google Scholar
• Via E, Cardoner N, Pujol J, et al. Amygdala activation and symptom dimensions in obsessive-compulsive disorder. Brit J Psychiatry. 2014;204(1):61–68.
   Web of Science ®Google Scholar
• Burton N. Neurotic, stress-related, and somatoform disorders (anxiety disorders), in Psychiatry. 2nd ed. Oxford: Blackwell; 2010. p.125–127.
   Google Scholar
• Cicek E, Cicek IE, Kayhan F, et al. Quality of life, family burden and associated factors in relatives with obsessive-compulsive disorder. Gen Hosp Psychiatry. 2013;35(3):253–258.
   Web of Science ®Google Scholar
• Brakoulias V, Starcevic V, Albert U, et al. Treatments used for obsessive-compulsive disorder – an international perspective. Hum Psychopharmacol. 2019;34(1):e2686.
   PubMed Web of Science ®Google Scholar
• Albert U, Marazziti D, Di Salvo G, et al. A systematic review of evidence-based treatment strategies for obsessive-compulsive disorder resistant to first-line pharmacotherapy. Curr Med Chem. 2018;25(41):5647–5661.
   PubMed Web of Science ®Google Scholar
• Zhou DD, Zhou XX, Li Y, et al. Augmentation agents to serotonin reuptake inhibitors for treatment-resistant obsessive-compulsive disorder: a network meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2019;2(90):277–287.
   Google Scholar
• Pignon B, Tezenas du Montcel C, Carton L, et al. The place of antipsychotics in the therapy of anxiety disorders and obsessive-compulsive disorders. Curr Psychiatry Rep. 2017;7(12):103.
   Google Scholar
• Dolda M, Aigner M, Lanzenberger R, et al. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: an update meta-analysis of double-blind, randomized, placebo-controlled trials. Int J Neuropsychopharmacol. 2015 Jul;18(9):47.
   Web of Science ®Google Scholar
• Zhou DD, Zhou XX, Lv Z, et al. Comparative efficacy and tolerability of antipsychotics as augmentations in adults with treatment-resistant obsessive-compulsive disorder: a network meta-analysis. J Psychiatr Res. 2019;14(111):51–58.
   Google Scholar
• Brakoulias V, Stockings E. A systematic review of the use of risperidone, paliperidone and aripiprazole as augmenting agents for obsessive-compulsive disorder. Expert Opin Pharmacother. 2018;26:1–7.
   Google Scholar
• Kordon A, Wahl K, Koch N, et al. Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol. 2008;28(5):550–554.
   PubMed Web of Science ®Google Scholar
• Carey PD, Vythilingum B, Seedat S, et al. Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study. BMC Psychiatry. 2005;24(5):5.
   Google Scholar
• Denys D, Geus F, Megen HJ, et al. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry. 2004;65(8):1040–1048.
   PubMed Web of Science ®Google Scholar
• Fineberg NA, Stein DJ, Premkumar P, et al. Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: a meta-analysis of randomized controlled treatment trials. Int Clin Psychopharmacol. 2006;21(6):337–343.
   Web of Science ®Google Scholar
• Pessina E, Albert U, Bogetto F, et al. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week open-label preliminary study. Int Clin Psychopharmacol. 2009;24(5):265–269.
   PubMed Web of Science ®Google Scholar
• Muscatello MR, Bruno A, Pandolfo G, et al. Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol. 2011;31(2):174–179.
   PubMed Web of Science ®Google Scholar
• Delle Chiaie R, Scarciglia P, Pasquini M, et al. Aripiprazole augmentation in patients with resistant obsessive compulsive disorder: a pilot study. Clin Pract Epidemiol Ment Health. 2011;7:107–111.
   PubMedGoogle Scholar
• Ak M, Bulut SD, Bozkurt A, et al. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 10-week open-label study. Adv Ther. 2011;28(4):341–348.
   PubMed Web of Science ®Google Scholar
• Ardic U A, Ercan ES, Kutlu A, et al. Successful treatment response with aripiprazole augmentation of SSRIs in refractory obsessive-compulsive disorder in childhood. Child Psychiatry Hum Dev. 2017;48(5):699–704.
   Web of Science ®Google Scholar
• Hegde D, Kalyani G, Arumugham SS, et al. Aripiprazole augmentation in highly treatment-resistant obsessive-compulsive disorder – experience from a specialty clinic in India. Int J Psychiatry Clin Pract. 2017;21(1):67–69.
   PubMed Web of Science ®Google Scholar
• Schulz KF, Altman DG, Moher D, CONSORT. Statement: updated guidelines for reporting parallel group randomized trials. Lancet. 2010;2010:1–6.
   Google Scholar
• American psychiatric association. Diagnostic and statistical manual of mental disorders. 4th ed. Text rev. Washington (DC): American Psychiatric Association; 2000. p. 262–270.
   Google Scholar
• Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown obsessive compulsive Scale, 1: development, use, and reliability. Arch Gen Psychiatry. 1998;46:1006–1011.
   Google Scholar
• Clinical Global Impressions. ECDEU assessment manual for psychopharmacology. In: Guy W, Rockville: U.S Department of Health, Education, and Welfare; 1976. DHEW Publication NO .(ADM) 76-338.
   Google Scholar
• Weiss E, Potenza MN, McDougle CJ, et al. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors; an open-label case series. J Clin Psychiatry. 1999;60:524–527.
   PubMed Web of Science ®Google Scholar
• Francobandiera G. Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study. Can J Psychiatry. 2001;46:356–358.
   PubMed Web of Science ®Google Scholar
• http://www.medcalc.be/30-
   Google Scholar
• Markarian Y, Larson MJ, Aldea MA, et al. Multiple pathways to functional impairment in obsessive-compulsive disorder. Clin Psychol Rev. 2010;30:78–88.
   PubMed Web of Science ®Google Scholar
• Bloch MH, Craiglow BG, Landeros-Weisenberger A, et al. Predictors of early adult outcomes in pediatric-onset obsessive-compulsive disorder. Pediatrics. 2009;124(4):1085–1093.
   PubMed Web of Science ®Google Scholar
• Jakubovski E, Bartley CA, Pittenger C, et al. Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis. J Clin Psychiatry. 2016;77(5):e605–e611.
   Web of Science ®Google Scholar
• Stein DJ, Subramanian G, Smith B, et al. Mavoglurant augmentation in OCD patients resistant to Selective serotonin reuptake inhibitors: a proof-of-Concept, randomized, placebo-controlled, Phase 2 study. Adv Ther. 2017;34(2):524–541.
   Web of Science ®Google Scholar
• Diniz JB, Requena G, Joaquim MA, et al. Randomized, double-blind, placebo-controlled trial of N-acetylcysteine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2017;78(7):e766–e773.
   Web of Science ®Google Scholar
• Paydary K, Akamaloo A, Ahmadipour A, et al. N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial. J Clin Pharm Ther. 2016;41(2):214–219.
   PubMed Web of Science ®Google Scholar
• Bloch MH, Storch EA. Assessment and management of treatment-refractory obsessive-compulsive disorder in Children. J Am Acad Child Adolesc Psychiatry. 2015;54(4):251–262.
   PubMed Web of Science ®Google Scholar
• Bloch MH, Landeros-Weisenberger A, Kelmendi B, et al. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry. 2006;11(7):622–632.
   PubMed Web of Science ®Google Scholar
• Li X, May RS, Tolbert LC, et al. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study. J Clin Psychiatry. 2005;66(6):736–743.
   PubMed Web of Science ®Google Scholar
• Maina G, Pessina E, Albert U, et al. 8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Eur Neuropsychopharmacol. 2008;18(5):364–372.
   PubMed Web of Science ®Google Scholar
• Selvi Y, Atli A, Aydin A, et al. The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomized study. Hum Psychopharmacol. 2011;26(1):51–57.
   PubMed Web of Science ®Google Scholar
• McDougle CJ, Epperson CN, Pelton GH, et al. A double-blind, placebo-controlled study of resperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry. 2000;57:794–801.
   PubMed Web of Science ®Google Scholar
• Komossa K, Depping AM, Meyer M, et al. Second-generation antipsychotics for obsessive compulsive disorder. Cochrane Database Syst Rev. 2010;8(12):CD008141.
   Google Scholar
• Bangalore S, Messerli FH. Of statistical significance: “trends” toward significance and optimism bias. J Am College Cardiol. 2006;48(7):66–74.
   Web of Science ®Google Scholar
• Wood J, Freemantle N, King M, et al. Trap of trends to statistical significance: likelihood of near significant P value becoming more significant with extra data. Br Med J. 2014;348:2215.
   PubMed Web of Science ®Google Scholar
• Matsunaga H, Nagata T, Hayashida K, et al. A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder. J Clin Psychiatry. 2009;70(6):863–868.
   PubMed Web of Science ®Google Scholar